- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Efficacy and safety evaluation of the peptide candidate CBT-001-839 for CAIX-targeted cancer diagnostic and therapeutic radiopharmaceuticals | ||||||
| Peptide | ccRCC | CAIX | Candidate | C-BIOMEX | RS-2023-00218641 | ||
| 2 | Development of personalized cancer vaccine against advanced stage lung cancer patients with immunotherapy resistance | ||||||
| Peptide | Lung cancer | Tumor specific neoantigens predicted from deep learning platform technology | Candidate | Penta Medix | RS-2022-00166187 | ||
| 3 | Development of tumor-derived exosome rupture peptide for combinational immunotherapy of colorectal cancer | ||||||
| Peptide | Colorectal cancer | Phopholipid layer | Hit | Sungkyunkwan University | HN22C0624 | ||
| 4 | Development of peptide vaccine against the pancreatic or lung cancers with KRAS mutation | ||||||
| Peptide | Pancreatic cancer, Lung cancer | KRAS mutant | Candidate | NA Vaccine Institute | HN21C1308 | ||